Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

ESC/EAS TASK FORCE ON PCSK9 INHIBITION

Why we need PCSK9 inhibitors: goal attainment too low with statin plus ezetimibe

Why we need PCSK9 inhibitors: goal attainment too low with statin plus ezetimibe

Guidelines recommend adding ezetimibe if patients fail to attain LDL cholesterol goal on statin alone. However, this study concludes that in a real-world setting, addition of ezetimibe had only a small impact on the number of high risk patients achieving an LDL cholesterol <1.8 mmol/L…

read more »
PlayESC/EAS Task Force issues updated clinical guidance for PCSK9 inhibitors

ESC/EAS Task Force issues updated clinical guidance for PCSK9 inhibitors

This Task Force from the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) has considered new evidence from cardiovascular outcomes studies with evolocumab (FOURIER) and bococizumab (now terminated), new analyses and genetic studies.t Taking account of the cost of these agents, the Task…

read more »